Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Segmental Overgrowth Syndrome
NCT02569125Phase 2Withdrawn
- Start
- Jan 2016
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in segmental overgrowth syndrome. Planned start Jan 2016; status: withdrawn.
02
Drugs
everolimus
03
Conditions
segmental overgrowth syndrome
Beyond the preview
Go deeper on NCT02569125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569125.